Inactive Instrument

News Intercept Pharmaceuticals, Inc.

Equities

ICPT

US45845P1084

Summary

Unlock all the news: Be the first to know and act before the market!

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024	04/06	CI
Intercept Pharmaceuticals, Inc. Presents New Sub-Analyses of Phase 3 POISE Data Showcasing the Effect of OCA on Key Liver Biomarkers and Fibrosis in Patients with PBC at Digestive Disease Week 2024	20/05	CI
Intercept Pharmaceuticals, Inc. Presents New Data Demonstrating the Impact of OCA-Bezafibrate Combination Therapy on Alp and Metabolic Outcomes After Six Months of Treatment At Digestive Disease Week®? 2024	18/05	CI
Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference	09/05	AQ
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC	29/02	AQ
North American Morning Briefing : Caution Dominates Ahead of CPI Print	14/11	DJ
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023	13/11	AQ
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023	13/11	CI
Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023	10/11	AQ
Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023	10/11	CI
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.	09/11	AQ
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.	08/11	AQ
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Composite Index	08/11	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P TMI Index	08/11	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Global BMI Index	08/11	CI
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from S&P Biotechnology Select Industry Index	08/11	CI
Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc..	08/11	CI
Intercept: Q3 Earnings Snapshot	07/11	AQ
North American Morning Briefing : Higher Bond -2-	07/11	DJ
Intercept Pharmaceuticals, Inc.(NasdaqGS:ICPT) dropped from NASDAQ Biotechnology Index	07/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Intercept Pharmaceuticals, Inc.

Equities

ICPT

US45845P1084

Summary

Filters